Mira seeks to buy Skny for its preclinical obesity, smoking cessation asset

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals in a deal that would give it control of a preclinical prospect and add $5 million to its bank balance.